Hematologic Malignancies: Treatment Strategies and Future Challenges
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Hematology".
Deadline for manuscript submissions: 26 June 2025 | Viewed by 4661
Special Issue Editor
Special Issue Information
Dear Colleagues,
We would appreciate it if you would contribute to the upcoming special issue of the Journal of Clinical Medicine, "Hematologic Malignancies: Treatment Strategies and Future Challenges". Hematologic malignancies are among the most prevalent cancers, and their incidence has increased in recent decades. Despite clinical progress, challenges such as relapse, refractory cases, and drug resistance still remain. The main purpose of this research theme is to introduce current therapeutic strategies and, as future challenges, to explore the future of hematologic malignancies, such as discovery of new targets or biomarkers and epigenetic drugs. It also includes the development of novel drugs in combination with conventional chemotherapeutic agents to reduce side effects and resistance in hematologic malignancies. Authors are encouraged to submit original research papers, reviews. We encourage submissions that provide new insights into underlying proliferation and resistance mechanisms in the treatment of hematological malignancies and discuss the clinical implications of these findings. After submission, all manuscripts are peer-reviewed according to standard journal procedures and policies. We hope that you will accept this invitation and contribute to the success of this special issue. We look forward to working with you.
Dr. Masaaki Noguchi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- hematologic malignancies
- relapse
- refractory
- drug resistance
- therapeutic strategies
- new target
- biomarkers
- new insights
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.